Q&A
Exclusive interviews with industry leaders
-
iStock via Getty Images
As the opioid crisis seethes, a long-lasting treatment could offer new ammunition
Launched this month, Brixadi from Braeburn gives patients a new tool to overcome addiction.
Michael Gibney • Sept. 21, 2023 -
saengsuriya13 via Getty Images
In the renal space, innovation could tackle health disparities. But the system doesn’t reward it.
Reimbursement challenges have created barriers for new dialysis products, according to the chief commercial officer of CorMedix.
Michael Gibney • Sept. 14, 2023 -
iStock via Getty Images
‘We need to do better:’ A biotech CEO on standing apart from the crowd
The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.
Michael Gibney • Aug. 29, 2023 -
Chip Somodevilla / Staff via Getty Images
A leading Democrat reveals how his mental health struggles shape his policy approach
Seattle Congressman Adam Smith's journey with anxiety and chronic health has influenced his perspective on healthcare and pharmaceutical policy.
Karissa Waddick • Aug. 17, 2023 -
Stock via Getty Images
Riding the mRNA wave, HDT Bio closes in on cancer-fighting vaccine
The company believes its platform could deliver safer and more efficient mRNA options for cancer and infectious diseases.
Kelly Bilodeau • Aug. 14, 2023 -
Permission granted by Lundbeck
5 minutes with — Lundbeck CEO Dr. Deborah Dunsire
The long-time pharma exec on her most recent wins, her favorite rule to break and the words she lives by.
Meagan Parrish • Aug. 11, 2023 -
Permission granted by Tessera
Why AbbVie’s former president has high hopes for this Flagship-backed biotech
The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.
Karissa Waddick • Aug. 7, 2023 -
iStock via Getty Images
How CymaBay overcame a NASH failure for another shot at liver disease success
The biotech’s 2019 trial halt was a major disappointment in NASH, but a turnaround has shown late-stage potential in another liver disease with unmet needs.
Michael Gibney • Aug. 2, 2023 -
iStock via Getty Images
With OTC birth control approved, access battles have just begun
Perrigo received the first FDA approval for an OTC birth control pill. Now, its global VP of women’s health says the company is working on the next challenge — affordability.
Karissa Waddick • July 26, 2023 -
Permission granted by Affini-T Therapeutics
In fast-growing KRAS field, this oncology veteran is chasing the toughest cancer targets
Loïc Vincent, chief scientific officer at Affini-T, explains the company’s T cell approach and latest moves toward the clinic.
Alexandra Pecci • July 25, 2023 -
Permission granted by Worldwide Clinical Trials
A leading CRO’s chief exec on why a ‘brave new world’ of clinical research is here
Peter Benton, co-CEO of Worldwide Clinical Trials, explains how the rise of the mid-sized pharma company has changed drug R&D.
Taren Grom and Meagan Parrish • July 20, 2023 -
iStock via Getty Images
Google for genes? This AI company aims to curate the entire human genome.
Genomenon’s acquisition of their contract scientific partner Boston Genetics will help them unlock the potential of genetic knowledge.
Michael Gibney • July 20, 2023 -
iStock via Getty Images
As biologics boom, here’s how manufacturers are keeping up
Stevanato’s focus on biologic-related vials and delivery devices has put it in a unique position amid a quickly growing market.
Michael Gibney • July 19, 2023 -
Stock via Getty Images
A rare disease veteran, Inozyme’s new CEO sharpens the company’s focus
After taking the reins from the company’s founding CEO, Douglas Treco is guiding Inozyme through the clinic.
Alexandra Pecci • July 11, 2023 -
Permission granted by Onyx Equities
Merck’s New Jersey campus is getting a biotech makeover
With a purchase of the pharma giant’s Kenilworth campus, Onyx Equities is looking to make the spot a go-to biotech hub.
Michael Gibney • July 11, 2023 -
Stock via Getty Images
A BMS exec’s journey around the world in 90 days
As BMS grapples with upcoming patent cliffs, Emma Charles, the new SVP of intercontinental markets, is focused on expanding its footprint.
Karissa Waddick • July 5, 2023 -
Courtesy of Sanofi
How Sanofi is taking a ‘creative’ approach to dealmaking
Dr. Monika Vnuk, SVP of global partnering and business development, is setting her sights on out-of-the-box partnerships.
Taren Grom • June 23, 2023 -
Stock via Getty Images
DIA’s chief exec is on a mission to grow its footprint across healthcare
Marwan Fathallah came onboard earlier this year to lead the organization into an era of change.
Michael Gibney • June 22, 2023 -
Stock via Getty Images
Ranking reveals biopharma’s most innovative companies
IDEA Pharma’s 12th index finds that Pfizer and AstraZeneca reign supreme again.
Taren Grom • June 7, 2023 -
Permission granted by Takeda
How Takeda finds the hottest new science to fuel its oncology work
Takeda's president of the global oncology business unit is always "scanning the horizon" for the partnerships that will drive the next big innovations.
Michael Gibney • June 1, 2023 -
Stock via Getty Images
From farm to pharma: How cows could play a role in the next flu breakthrough
SAb Biotherapeutics is working on a novel product that uses cow antibodies genetically engineered into human antibodies to prevent and treat infectious diseases.
Alexandra Pecci • May 16, 2023 -
Permission granted by Christopher Boone AbbVie
AbbVie’s Christopher Boone on RWE’s potential — and its ‘profound ethical dilemmas’
With decades of experience in public health, Boone is leveraging RWE to move the needle within clinical development.
Taren Grom • May 10, 2023 -
Permission granted by Bahija Jallal
How Immunocore’s Bahija Jallal embraced the ‘a-ha’ moment of promising science
The biotech CEO is bullish on the company’s pioneering T cell receptor platform and innovating new immunology-based treatments.
Taren Grom • May 5, 2023 -
Permission granted by Genmab
From science to strategy, this exec is painting Genmab’s bigger picture into the next decade
Martine van Vugt, recently named Genmab’s chief strategy officer and executive vice president, aims to usher in the company’s next wave of "knock your socks off" antibodies.
Michael Gibney • May 2, 2023 -
Permission granted by Kurt Harrington
A CEO’s quest to solve a 400-year-old medical mystery — and he’s also a patient
The CEO of Ventoux Biosciences has the disease that his company is aiming to treat, and it's driving him to find better medications.
Taren Grom • May 1, 2023
